This guideline covers the care and treatment of people with, or at risk of developing, chronic kidney disease. It aims to prevent or delay the progression of chronic kidney disease, reduce or prevent the development of complications, and reduce the risk of cardiovascular disease.
NICE has produced a COVID-19 rapid guideline on chronic kidney disease. It recommends changes to usual practice to maximise the safety of patients and protect staff from infection during the COVID-19 pandemic.
This guideline includes recommendations on:
Who is it for?
- Healthcare professionals
- Commissioners and providers
- People with chronic kidney disease, their families and carers
Is this guideline up to date?
We checked this guideline in April 2017 and are updating the recommendations on investigations for and classification of chronic kidney disease (CKD), defining progression and anaemia identification in people with CKD.
See the guideline in development page for progress on the update.
Guideline development process
How we develop NICE guidelines
This guideline updates and replaces NICE guideline CG73 (September 2008).
This guideline was previously called chronic kidney disease: early identification and management of chronic kidney disease in adults in primary and secondary care.
The recommendations in this guideline represent the view of NICE, arrived at after careful consideration of the evidence available. When exercising their judgement, professionals and practitioners are expected to take this guideline fully into account, alongside the individual needs, preferences and values of their patients or the people using their service. It is not mandatory to apply the recommendations, and the guideline does not override the responsibility to make decisions appropriate to the circumstances of the individual, in consultation with them and their families and carers or guardian.
All problems (adverse events) related to a medicine or medical device used for treatment or in a procedure should be reported to the Medicines and Healthcare products Regulatory Agency using the Yellow Card Scheme.
Local commissioners and providers of healthcare have a responsibility to enable the guideline to be applied when individual professionals and people using services wish to use it. They should do so in the context of local and national priorities for funding and developing services, and in light of their duties to have due regard to the need to eliminate unlawful discrimination, to advance equality of opportunity and to reduce health inequalities. Nothing in this guideline should be interpreted in a way that would be inconsistent with complying with those duties.
Commissioners and providers have a responsibility to promote an environmentally sustainable health and care system and should assess and reduce the environmental impact of implementing NICE recommendations wherever possible.